Comirnaty COVID-19 vaccine: how Pfizer’s mRNA shot fits today

Pfizer’s Comirnaty COVID-19 vaccine remains a key mRNA option for U.S. adults and teens, with strain-updated formulas reviewed regularly by U.S. and EU regulators for ongoing protection needs.

Pfizer Comirnaty is the brand name for the Pfizer-BioNTech COVID-19 mRNA vaccine, authorized in multiple updated formulations as regulators continue to review which coronavirus strains new shots should target for upcoming seasons FDA, 04/30/2024.

As of: 06/08/2026 | Reading time: approx. 7 minutes

By the AD HOC NEWS editorial team - specialized in product-focused market coverage.

At a Glance

• Product: Pfizer Comirnaty COVID-19 vaccine
• Category: mRNA-based COVID-19 vaccine
• Brand/Manufacturer: Pfizer and BioNTech
• Primary Use Cases: Prevention of symptomatic COVID-19
• Availability: Widely available via U.S. vaccination providers
• Core Markets: United States, European Union, global

What Pfizer Comirnaty COVID-19 vaccine is and how it works

Comirnaty is an mRNA vaccine that delivers genetic instructions for human cells to produce the SARS-CoV-2 spike protein, training the immune system to recognize and respond to the virus without using live virus in the shot FDA, 01/31/2024.

The vaccine uses lipid nanoparticles to protect and transport the fragile mRNA into cells, where it is translated into spike protein fragments that prompt an immune response and the development of antibodies and T-cell responses against COVID-19 CDC, 03/15/2024.

Different formulations of Comirnaty have been authorized over time, including original, bivalent, and monovalent strain-updated versions that align with circulating Omicron-lineage variants as recommended by health authorities EMA, 02/20/2025.

Why Pfizer Comirnaty COVID-19 vaccine matters for US consumers and industry

In the United States, Comirnaty has been a cornerstone of national COVID-19 vaccination campaigns and remains one of the primary mRNA options used in pharmacies, clinics, and health systems across the country CDC, 02/01/2025.

Regulators periodically review which variants new vaccine formulations should target; for the 2025-2026 and 2026-2027 seasons, FDA advisers have evaluated updated compositions to better match circulating strains, which can include candidates from mRNA manufacturers like Pfizer The Straits Times, 05/28/2026.

For U.S. consumers, Comirnaty offers a familiar option that many providers already store and administer, which can simplify scheduling booster doses for adults and eligible adolescents under evolving public health recommendations CDC, 02/01/2025.

Pfizer Comirnaty COVID-19 vaccine in the US and global market

Comirnaty has played a central role in global vaccination efforts and continues to be supplied under updated strain-specific contracts in regions such as the European Union and North America, subject to ongoing regulatory review and demand BioNTech, 01/30/2025.

In the United States, distribution of updated Comirnaty formulations occurs through commercial channels including retail pharmacies, hospital systems, and public health programs, alongside other COVID-19 vaccines such as those from Moderna and Novavax CDC, 02/01/2025.

Outside the U.S., regulators such as the European Medicines Agency continue to assess new Comirnaty adaptations that target emerging strains, with decisions influencing product availability and vaccination strategies in EU member states EMA, 02/20/2025.

• mRNA technology for flexible variant updates
• Multiple authorized formulations over time
• Wide distribution through U.S. pharmacies and clinics
• Ongoing regulatory review of strain composition
• Used for primary series and booster doses where recommended

Frequently Asked Questions About Pfizer Comirnaty COVID-19 vaccine

Is Comirnaty an mRNA vaccine?
Yes, Comirnaty uses messenger RNA to teach the body to recognize the SARS-CoV-2 spike protein, helping the immune system respond to the virus without using live virus.

Where can I get Comirnaty in the US?
In the U.S., updated COVID-19 vaccines such as Comirnaty are typically available at pharmacies, clinics, and health systems, often scheduled through online or pharmacy apps.

Who decides which strain Comirnaty targets?
Regulators and advisory groups, including the U.S. FDA and global health bodies, review data on circulating variants and recommend which strain updated COVID-19 vaccines should target for future seasons.

Pfizer Inc. co-develops and commercializes Comirnaty with its partner BioNTech SE under a long-term collaboration focused on mRNA-based vaccines and therapies.

Pfizer Inc. is listed on the New York Stock Exchange under the ticker PFE, and its registered shares carry the ISIN US7170811035 as a key security identifier.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.